Searched for
GENERIC BUSINESS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...12 Jun, 2026, 12.25 PM IST- The future of AI may be a world where nobody talks about AIhe first wave of artificial intelligence was defined by models, capabilities, and technical breakthroughs. The next may be defined by somet...11 Jun, 2026, 05.32 PM IST
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...11 Jun, 2026, 10.31 AM IST
- Meta launches business agent AI to automate customer service, sales and business operationsMeta has unveiled Meta Business Agent, an AI-powered assistant designed to help businesses automate customer support, sales, scheduling and...10 Jun, 2026, 11.07 AM IST
- Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...10 Jun, 2026, 09.05 AM IST
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...09 Jun, 2026, 07.34 PM IST
- Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 croreViyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion...08 Jun, 2026, 05.58 PM IST
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...08 Jun, 2026, 02.25 PM IST
- AI isn’t just for large enterprises: Xebia's Anand Sahay on why MSMEs could be AI’s biggest winnersAs India accelerates its sovereign AI ambitions, the focus is shifting from infrastructure to outcomes, how businesses can harness AI to im...08 Jun, 2026, 10.23 AM IST
- How to make poverty disappear: Never mind trickle-down effect, or the rising tide that'll lift all boatsIn a provocative article, the writer proposes an extreme measure to combat poverty: the complete elimination of the poor. While this radica...06 Jun, 2026, 10.22 PM IST
- Business Quote of the day by Ray Kroc: ‘No self-respecting salesman makes the same…’ Key sales insight by the man behind transformation of McDonald’sRay Kroc, the man behind McDonald's global success, believed in tailoring pitches. He compared sales to baseball, stating no two clients ar...06 Jun, 2026, 01.29 PM IST
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...03 Jun, 2026, 08.17 PM IST
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...03 Jun, 2026, 02.36 PM IST
- India Inc sails past fourth-quarter estimates, but oil shock clouds outlookIndian companies achieved better-than-expected profits in the March quarter. Domestic activity was strong, supported by tax cuts and easy m...02 Jun, 2026, 02.52 PM IST
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...01 Jun, 2026, 01.29 PM IST
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...31 May, 2026, 01.34 PM IST
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...29 May, 2026, 05.30 AM IST
Load More
